

Amendments to the Claims:

Please amend the claims to read as follows:

1 - 8. (Cancelled)

9. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a catechin and a pharmaceutically acceptable carrier, diluent, or excipient, the therapeutic amount of the catechin selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.

10. (Previously Amended) The composition of claim 9 wherein the therapeutically effective amount of the catechin comprises a dosage in the range of about 10 to 1,000 mg/kg of body weight of the subject.

11. (Original) The composition of claim 10 wherein the therapeutically effective amount of the catechin comprises a dosage in the range of about 10 to 100 mg/kg of body weight of the subject.

12. (Currently Amended) The composition of claim 9 wherein the catechin is selected from the group consisting of catechin, epicatechin, gallic catechin gallate, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts of the foregoing catechins.

13. (Currently Amended) The composition of claim 12 comprising a mixture of two or more of the catechins selected from the group consisting of catechin, epicatechin, gallic catechin gallate, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts of the foregoing catechins.

14. (Original) The composition of claim 12 wherein each catechin selected is present in a percentage purity that significantly exceeds a proportion percentage of the catechin presence in a plant, or extract from a plant.

15. (Original) The composition of claim 15 wherein the catechin selected is in substantially pure isolated or synthetic form.

16. (Cancelled)

17. (Previously Added) A pharmaceutical composition consisting of a therapeutically effective amount of a catechin and of a pharmaceutically acceptable carrier, diluent, or excipient, the therapeutic amount of the catechin selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.

18. (Cancelled)